Topical calcipotriol in childhood psoriasis

Background: The use of topical calcipotriol in adults with psoriasis is safe and effective. Objective: Our purpose was to study the efficacy and safety of calcipotriol in children. Methods: A multicenter, prospective, 8-week, double-blind, parallel group study was conducted in 77 children. Response...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the American Academy of Dermatology Vol. 36; no. 2; pp. 203 - 208
Main Authors:	Oranje a, Arnold P., Marcoux b, Danielle, Svensson c, Åke, Prendiville d, Julie, Krafchik e, Bernice, Toole f, J, Rosenthal g, Donald, de Waard-van der Spek a, Flora B., Molin h, Lars, Axelsen i, Mads
Format:	Journal Article
Language:	English
Published:	New York, NY Mosby, Inc 01-02-1997 Elsevier
Subjects:	Administration, Topical Adolescent Analysis of Variance Biological and medical sciences Biomarkers - blood Calcitriol - administration & dosage Calcitriol - adverse effects Calcitriol - analogs & derivatives Child Child, Preschool Dermatologic Agents - administration & dosage Dermatologic Agents - adverse effects Dermatology Double-Blind Method Female Humans Male Medical sciences Patient Compliance Peptide Fragments - blood Procollagen - blood Prospective Studies Psoriasis - blood Psoriasis - drug therapy Psoriasis. Parapsoriasis. Lichen Human Skin disease Chemotherapy Psoriasis Treatment efficiency Calcipotriol Child Topical administration
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background: The use of topical calcipotriol in adults with psoriasis is safe and effective. Objective: Our purpose was to study the efficacy and safety of calcipotriol in children. Methods: A multicenter, prospective, 8-week, double-blind, parallel group study was conducted in 77 children. Response to treatment was assessed by means of the Psoriasis Area and Severity Index (PASI) in that the intensity of redness, thickness, and scaliness as well as the area involved are scored. The children were 2 to 14 years of age and had stable psoriasis, involving less than 30% of the body surface. Forty-three children were assigned to receive calcipotriol ointment and 34 to receive placebo. Nine children dropped out of the study, six in the calcipotriol-treated group and three in the placebo-treated group. Results: Both treatment groups (calcipotriol and placebo) showed significant improvement in PASI from baseline to the end of treatment, and the difference was not statistically significant. No serious side effects, in particular including those relating to calcium and bone metabolism, were recorded. Conclusion: Calcipotriol ointment was statistically significantly more effective than its vehicle in terms of the investigator's overall assessment and reduction in redness and scaliness but not in terms of PASI score. (J Am Acad Dermatol 1997;36:203-8.)
ISSN:	0190-9622 1097-6787
DOI:	10.1016/S0190-9622(97)70281-0